Role of hematopoietic stem cell transplantation in the treatment of non-Hodgkin's lymphoma

Philip Jay Bierman, Gordon L. Phillips

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Over the last 25 years the use of auto- and allogeneic HSCT for NHL increased dramatically. This therapy is being used for types of NHL that were not even defined when transplantation was first used. Although thousands of NHL patients have had their lives prolonged or have been cured with transplantation, the role of HSCT is still undefined in most situations. Unfortunately, HSCT is often used simply because satisfactory nontransplant options are unavailable. Allogeneic HSCT is often used because of the perception that autologous HSCT will be ineffective. Reduced-intensity allogeneic HSCT is often utilized in situations when definite evidence of superiority over myeloablative allogeneic HSCT, and even autologous HSCT, do not exist. Treatment decisions are even more difficult today because of better primary treatments and because of the introduction of effective new agents and targeted therapies for relapsed and refractory disease. It is hoped that the role of HSCT for NHL will be refined when results of ongoing phase III trials are available.

Original languageEnglish (US)
Pages (from-to)357-397
Number of pages41
JournalCancer Treatment and Research
Volume144
DOIs
StatePublished - 2009

Fingerprint

Hematopoietic Stem Cell Transplantation
Non-Hodgkin's Lymphoma
Transplantation
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Role of hematopoietic stem cell transplantation in the treatment of non-Hodgkin's lymphoma. / Bierman, Philip Jay; Phillips, Gordon L.

In: Cancer Treatment and Research, Vol. 144, 2009, p. 357-397.

Research output: Contribution to journalArticle

@article{f294dd0451144b0ca75f048b845225bd,
title = "Role of hematopoietic stem cell transplantation in the treatment of non-Hodgkin's lymphoma",
abstract = "Over the last 25 years the use of auto- and allogeneic HSCT for NHL increased dramatically. This therapy is being used for types of NHL that were not even defined when transplantation was first used. Although thousands of NHL patients have had their lives prolonged or have been cured with transplantation, the role of HSCT is still undefined in most situations. Unfortunately, HSCT is often used simply because satisfactory nontransplant options are unavailable. Allogeneic HSCT is often used because of the perception that autologous HSCT will be ineffective. Reduced-intensity allogeneic HSCT is often utilized in situations when definite evidence of superiority over myeloablative allogeneic HSCT, and even autologous HSCT, do not exist. Treatment decisions are even more difficult today because of better primary treatments and because of the introduction of effective new agents and targeted therapies for relapsed and refractory disease. It is hoped that the role of HSCT for NHL will be refined when results of ongoing phase III trials are available.",
author = "Bierman, {Philip Jay} and Phillips, {Gordon L.}",
year = "2009",
doi = "10.1007/978-0-387-78580-6-15",
language = "English (US)",
volume = "144",
pages = "357--397",
journal = "Cancer Treatment and Research",
issn = "0927-3042",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Role of hematopoietic stem cell transplantation in the treatment of non-Hodgkin's lymphoma

AU - Bierman, Philip Jay

AU - Phillips, Gordon L.

PY - 2009

Y1 - 2009

N2 - Over the last 25 years the use of auto- and allogeneic HSCT for NHL increased dramatically. This therapy is being used for types of NHL that were not even defined when transplantation was first used. Although thousands of NHL patients have had their lives prolonged or have been cured with transplantation, the role of HSCT is still undefined in most situations. Unfortunately, HSCT is often used simply because satisfactory nontransplant options are unavailable. Allogeneic HSCT is often used because of the perception that autologous HSCT will be ineffective. Reduced-intensity allogeneic HSCT is often utilized in situations when definite evidence of superiority over myeloablative allogeneic HSCT, and even autologous HSCT, do not exist. Treatment decisions are even more difficult today because of better primary treatments and because of the introduction of effective new agents and targeted therapies for relapsed and refractory disease. It is hoped that the role of HSCT for NHL will be refined when results of ongoing phase III trials are available.

AB - Over the last 25 years the use of auto- and allogeneic HSCT for NHL increased dramatically. This therapy is being used for types of NHL that were not even defined when transplantation was first used. Although thousands of NHL patients have had their lives prolonged or have been cured with transplantation, the role of HSCT is still undefined in most situations. Unfortunately, HSCT is often used simply because satisfactory nontransplant options are unavailable. Allogeneic HSCT is often used because of the perception that autologous HSCT will be ineffective. Reduced-intensity allogeneic HSCT is often utilized in situations when definite evidence of superiority over myeloablative allogeneic HSCT, and even autologous HSCT, do not exist. Treatment decisions are even more difficult today because of better primary treatments and because of the introduction of effective new agents and targeted therapies for relapsed and refractory disease. It is hoped that the role of HSCT for NHL will be refined when results of ongoing phase III trials are available.

UR - http://www.scopus.com/inward/record.url?scp=77953667888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953667888&partnerID=8YFLogxK

U2 - 10.1007/978-0-387-78580-6-15

DO - 10.1007/978-0-387-78580-6-15

M3 - Article

VL - 144

SP - 357

EP - 397

JO - Cancer Treatment and Research

JF - Cancer Treatment and Research

SN - 0927-3042

ER -